Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4280A vs regorafenib or trifluridine/tipiracine in metastatic colorectal cancer
CTR20220500Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of favezelimab + pembrolizumab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Mar 2022; status: completed.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220500.